Key Highlights

  • Zoono is offering one new share for every ten held at $0.039 each, aiming to raise approximately $1,609,226 before costs.
  • The offer opens on 3 November 2026 and closes at 5:00pm AEDT on 17 November 2026, unless lawfully extended.
  • Up to about 41,262,202 new shares may be issued, lifting shares on issue from 412,622,020 to roughly 453,884,222.
  • The largest planned expenditure is $350,000 for company secretarial, registry, ASX, audit and insurance costs, followed by $300,000 for packaging.

Zoono Group Limited (ASX:ZNO) released an offer document on 23 October 2026 for a pro rata non-renounceable rights issue to eligible shareholders. Under the terms, shareholders on the record date receive one new share for every ten existing shares held, at an issue price of $0.039 per new share, to raise approximately $1,609,226 before costs. The document is not a prospectus and was prepared under section 708AA of the Corporations Act, as modified by an ASIC instrument.

Offer Terms and Timetable

The offer opens on 3 November 2026 and closes at 5:00pm AEDT on 17 November 2026, unless the directors lawfully extend it. The ex date is 28 October and the record date is 29 October 2026. Results are due before noon on 24 November, when the new shares are also scheduled to be issued, with quotation expected on 25 November 2026.

The maximum issue is about 41,262,202 shares, against 412,622,020 shares currently on issue, which include 6,410,256 shares issued on 23 October 2026 at $0.039 under the company's placement capacity. Eligible shareholders can also apply for additional shares under a shortfall offer, and the allocation policy is designed so that no person ends up holding more than 19.9% of shares on completion.

Planned Use of Funds

Zoono intends to apply the proceeds as follows: $300,000 for packaging for extended shelf-life, $50,000 for China shelf-life expansion, $25,000 for India shelf-life expansion, $200,000 for patents and intellectual property, $240,000 for directors' fees, $120,000 for overheads, $350,000 for company secretarial, registry, ASX, audit, insurance and other costs, $273,000 for working capital and $51,226 for offer expenses. The board said the allocation may change and that, if the offer is undersubscribed, funds would be scaled back in a stated order, starting with packaging.

Why This Could Matter

The company said completion would add up to $1,609,226 in cash before costs and that the board believes it will then have sufficient working capital to achieve its stated objectives. Shareholders who do not take up entitlements would be diluted by approximately 9.1%, according to the document.

Managing Director Paul Hyslop holds 119,629,246 shares, or 28.99% voting power, with an entitlement of 11,962,925 shares. He has indicated he intends to take up a substantial proportion, though not necessarily all, of it. Don Clarke and Elissa Hansen have agreed to take up their entitlements in full. On the document's scenarios, Mr Hyslop's maximum voting power would range from 28.99% to 30.99%, depending on take-up by others.

Where Things Stand

The offer document sets out an indicative path from the 29 October record date to quotation on 25 November 2026. Shareholders in Australia, New Zealand, Germany, Hong Kong, Singapore and the United Kingdom are eligible, subject to the document's conditions.